...
首页> 外文期刊>Journal of orthopaedic science : >Recurrent epithelioid hemangioma: therapeutic potential of tranilast and indomethacin.
【24h】

Recurrent epithelioid hemangioma: therapeutic potential of tranilast and indomethacin.

机译:复发性上皮样血管瘤:曲尼司特和消炎痛的治疗潜力。

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction:Epithelioid hemangioma (EH), also known as angiolym-phoid hyperplasia with eosinophilia, is a benign vascular proliferation of unknown etiology that was firstly described in 1969 [1]. It typically affects the skin and subcutaneous tissue of the head and neck, but it uncommonly arises in other sites. Although this tumor is classified as a benign vascular tumor in the World Health Organization (WHO) classification published in 2002 [2], local recurrence is reported to occur in up to one-third of patients [3]. Complete excision and intensive follow up are thought to be optimum management for EH and no other treatment modalities are established [3]. We report a case with recurrent epithelioid hemangioma who underwent pharmacological treatment combined with tranilast and indomethacin and showed marked regression almost completely. To our knowledge, this is the first report demonstrating the potency of combined tranilast and indomethacin drug therapy.
机译:简介:上皮样血管瘤(EH),又称嗜酸性粒细胞增生的淋巴管增生,是一种病因不明的良性血管增生,最早在1969年被描述[1]。它通常会影响头和颈部的皮肤和皮下组织,但不常见于其他部位。尽管该肿瘤在2002年发布的世界卫生组织(WHO)分类中被分类为良性血管肿瘤[2],但据报道局部复发的患者多达三分之一[3]。完全切除和强化随访被认为是EH的最佳治疗方法,尚无其他治疗方式确立[3]。我们报告了一例复发性上皮样血管瘤,该患者接受了曲尼司特和消炎痛的联合药物治疗,并且几乎完全消失。据我们所知,这是第一份证明曲尼司特和消炎痛联合药物治疗的效力的报告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号